Literature DB >> 16775572

Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock.

Linda A Kirschenbaum1, Wilma Correa Lopez, Patricia Ohrum, Anita Tsen, John Khazin, Mark E Astiz.   

Abstract

OBJECTIVE: To examine the effects of recombinant activated protein C (rhAPC) and low-dose heparin on neutrophil-platelet-endothelial cell interactions in septic shock.
DESIGN: Controlled experiments using phase contrast microscopy to study neutrophil, platelet, and endothelial cell interactions in flowing cell suspensions under simulated physiologic conditions.
SETTING: University research laboratory. PATIENTS: Adult patients with septic shock and normal volunteers.
INTERVENTIONS: Neutrophils and platelets removed from control subjects were stimulated with plasma and serum from 21 patients in septic shock and perfused over endothelial cells. Activated protein C, low-dose heparin, and low-dose heparin with rhAPC were added to cells suspended in septic plasma. Neutrophil rolling velocity and the number of neutrophils adherent to endothelial cells and in aggregates were determined. Flow cytometric analysis of CD11b/CD63 cells was used to identify platelet-neutrophil aggregates.
MEASUREMENTS AND MAIN RESULTS: Activated protein C significantly decreased neutrophil adhesion and aggregation and increased rolling velocity in cells stimulated with both septic serum and septic plasma. Significant decreases in platelet-neutrophil aggregates induced by septic plasma were also observed. Low-dose heparin alone had no effects on these variables. The addition of low-dose heparin to cells suspended in septic plasma and rhAPC attenuated the benefits observed with rhAPC alone in each of these variables.
CONCLUSIONS: These data suggest that the in vitro addition of rhAPC decreases sepsis-induced interactions between isolated platelets, neutrophils, and endothelial cells. Low-dose heparin attenuates the benefits observed with rhAPC. The changes in neutrophil-endothelial cell interactions demonstrated with rhAPC may play a role in preserving microvascular patency in patients with septic shock.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775572     DOI: 10.1097/01.CCM.0000229880.41513.86

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Hypoxia attenuates effector-target cell interaction in the airway and pulmonary vascular compartment.

Authors:  S Meyer; B R Z'graggen; S Blumenthal; A Borgeat; M T Ganter; L Reyes; C Booy; T A Neff; D R Spahn; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2007-09-24       Impact factor: 4.330

Review 2.  Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

Authors:  Daniel De Backer
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.

Authors:  Johannes Daan de Boer; Liesbeth M Kager; Joris J T H Roelofs; Joost C M Meijers; Onno J de Boer; Hartmut Weiler; Berend Isermann; Cornelis van 't Veer; Tom van der Poll
Journal:  BMC Infect Dis       Date:  2014-11-04       Impact factor: 3.090

Review 4.  Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis.

Authors:  Changsong Wang; Chunjie Chi; Lei Guo; Xiaoyang Wang; Libo Guo; Jiaxiao Sun; Bo Sun; Shanshan Liu; Xuenan Chang; Enyou Li
Journal:  Crit Care       Date:  2014-10-16       Impact factor: 9.097

5.  CD63 and C3AR1: The Potential Molecular Targets in the Progression of Septic Shock.

Authors:  Ning Yu; Xuefang Liu; Dandan Shi; Long Bai; Tianfu Niu; Ya Liu
Journal:  Int J Gen Med       Date:  2022-01-19

6.  Is thenar tissue hemoglobin oxygen saturation in septic shock related to macrohemodynamic variables and outcome?

Authors:  Didier Payen; Cecilia Luengo; Laurent Heyer; Matthieu Resche-Rigon; Sébastien Kerever; Charles Damoisel; Marie Reine Losser
Journal:  Crit Care       Date:  2009-11-30       Impact factor: 9.097

7.  Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.

Authors:  Deven Juneja; S Mohan; Vivek V Veturi; Palepu B Gopal
Journal:  Indian J Crit Care Med       Date:  2009 Jul-Sep

8.  Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.

Authors:  Kristine Waerhaug; Vladimir N Kuklin; Mikhail Y Kirov; Mikhail A Sovershaev; Bodil Langbakk; Ole C Ingebretsen; Kirsti Ytrehus; Lars J Bjertnaes
Journal:  Crit Care       Date:  2008-08-15       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.